Predictive Value of Neovascularization Within Asymptomatic Carotis Stenosis on CEUS

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Nov 23, 2012

Keywords

ClinConnect Summary

This clinical trial is studying a new way to assess the risk of serious health issues, like heart attacks and strokes, in people who have narrowing (stenosis) of the carotid arteries but do not show any symptoms. Researchers want to see if a special ultrasound technique called contrast-enhanced ultrasound (CEUS) can detect new small blood vessels (neovascularization) that form within the plaque in these arteries. This could help identify patients at higher risk for future vascular problems, potentially allowing doctors to recommend earlier treatments.

To participate in the trial, individuals must be at least 18 years old and have at least 30% narrowing of the carotid artery without any history of stroke or similar events. Those with recent heart issues, severe heart or lung conditions, or who are pregnant cannot join. Participants will undergo non-invasive imaging to help assess their condition. The hope is that by identifying those with unstable plaques, doctors can better tailor treatment options, which may include surgical interventions. This trial is currently recruiting participants and aims to improve how we predict and manage risks associated with carotid stenosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients age \> 18 years
• • Asymptomatic (no history of cerebrovascular event in the corresponding vessel territory) ≥30% carotid stenosis on standard carotid ultrasound
• Exclusion Criteria:
• • History of previous carotid endarterectomy or carotid stenting.
• • Heart failure (HYHA III or IV)
• • Myocardial infarction (\<7d)
• • Severe pulmonal-arterial hypertension (pulmonal arterial pressure \>90mmHg) based on clinical information (history of pulmonal arterial pressure, dyspnea on exertion New York Heart Association (NYHA) III and NYHA IV)
• • pregnancy (pregnancy test in patients of childbearing age: \<50 years and/or less than 2 years after menopause)
• • Follow-up is not considered feasible